The publication last year of large trials of PSA screening in prostate cancer has rekindled interest in alternative noninvasive markers for this disease. Here, Ploussard and de la Taille discuss the range of potential urinary biomarkers in prostate cancer, and the current clinical data on their utility in disease detection and staging.
- Guillaume Ploussard
- Alexandre de la Taille
